Showing results (31-40 of 143) with videos related to

Sort By:
Pageof 15
Journal of Clinical Lipidology|December 3, 2010
When is equal not equal?Allan D Sniderman, Ken Williams, Matthew J McQueen, et al.
BMJ (Clinical Research Ed.)|June 16, 2011
Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trialsSonal Singh, Yoon K Loke, Paul L Enright, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|July 6, 2011
Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysisSonal Singh, Yoon K Loke, John G Spangler, et al.
The American Journal of Cardiology|January 12, 2005
Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project)Paul L Canner, Curt D Furberg, Michael L Terrin, et al.
Pharmacoepidemiology and Drug Safety|February 11, 2016
Completeness of serious adverse drug event reports received by the US Food and Drug Administration in 2014Thomas J Moore, Curt D Furberg, Donald R Mattison, et al.
JAMA|December 2, 2004
Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysisBruce M Psaty, Curt D Furberg, Wayne A Ray, et al.
Trials|March 25, 2006
Lead editorial: trials - using the opportunities of electronic publishing to improve the reporting of randomised trialsDouglas G Altman, Curt D Furberg, Jeremy M Grimshaw, et al.
Journal of Clinical Epidemiology|August 6, 2002
Predictors of subsequent coronary events, stroke, and death among survivors of first hospitalized myocardial infarctionRobert C Kaplan, Susan R Heckbert, Curt D Furberg, et al.
Mayo Clinic Proceedings|October 2, 2013
The necessity for clinical reasoning in the era of evidence-based medicineAllan D Sniderman, Kevin J LaChapelle, Nikodem A Rachon, et al.
American Journal of Hypertension|April 4, 2013
Renin-angiotensin system blockers may create more risk than reward for sodium-depleted cardiovascular patients with high plasma renin levelsJean E Sealey, Michael H Alderman, Curt D Furberg, et al.
Pageof 15